Grant: Doctoral: Vanier Canada Graduate Scholarships
University of Toronto
$150,000.00
Metabolic Reprogramming of Glioblastoma to Reduce Tumour Growth
FY 2017-18
Summary
Glioblastoma (GBM) is the most common and the most malignant brain tumour affecting both children and adults in North America. Despite decades of research, therapeutic options are limited for this deadly disease which has an average survival of approximately 12-16 months. One of the defining characteristics of GBM is altered tumour cell metabolism. Our group previously discovered a new enzyme called PTEN-induced Kinase 1 (PINK1) in GBM which helps to regulate the metabolism within the energy factory of cells called the mitochondria. Excitingly, when the function of this enzyme is increased, we observed that tumours shrink in our experimental models. As a Vanier Canada Graduate Scholar, I will be investigating exactly how PINK1 can be targeted therapeutically to establish new ways to reduce tumour growth and increase survival in this incurable disease.
Department
Program
Doctoral: Vanier Canada Graduate Scholarships
Recipient
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
376561
Name
Taccone Michael S
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Cancer Research
Theme2
Biomedical
Prcname2
Vanier Canada Graduate Scholarships CIHR
Projecttitle
Metabolic Reprogramming of Glioblastoma to Reduce Tumour Growth
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$150,000
Cihrequipment2
$0
Programname2
Doctoral: Vanier Canada Graduate Scholarships
Keyworddelim
Cell Biology; Glioma; Neuro-Oncology; Tumour Metabolism
Abstract
Glioblastoma (GBM) is the most common and the most malignant brain tumour affecting both children and adults in North America. Despite decades of research, therapeutic options are limited for this deadly disease which has an average survival of approximately 12-16 months. One of the defining characteristics of GBM is altered tumour cell metabolism. Our group previously discovered a new enzyme called PTEN-induced Kinase 1 (PINK1) in GBM which helps to regulate the metabolism within the energy factory of cells called the mitochondria. Excitingly, when the function of this enzyme is increased, we observed that tumours shrink in our experimental models. As a Vanier Canada Graduate Scholar, I will be investigating exactly how PINK1 can be targeted therapeutically to establish new ways to reduce tumour growth and increase survival in this incurable disease.
Competitiondate
201711
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Taccone, Michael S
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $150,000~ $0~